相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors
Aine O'Reilly et al.
SUPPORTIVE CARE IN CANCER (2020)
Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade
T. Gambichler et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
T. Sakakida et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Omar Hasan Ali et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients
Florence Joly et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Mark A. Perazella et al.
KIDNEY INTERNATIONAL (2020)
Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?
Diego Enrico et al.
CLINICAL CANCER RESEARCH (2020)
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer
Ganessan Kichenadasse et al.
JAMA ONCOLOGY (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman R. G. Stroud et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Checkpoint inhibitors and arthritis
Nicholas Manolios et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile
Silvio Danese et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
Andrew L. Mammen et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Immune checkpoint inhibitors and the development of granulomatous reactions
Christine M. Cornejo et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis
Janet Roberts et al.
CLINICAL RHEUMATOLOGY (2019)
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
Claire Perrinjaquet et al.
CURRENT OPINION IN NEUROLOGY (2019)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbe et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review
Evan T. Hall et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Glucocorticoids promote breast cancer metastasis
Milan M. S. Obradovic et al.
NATURE (2019)
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Karin H. Simons et al.
NATURE REVIEWS CARDIOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Hematologic Complications of Immune Checkpoint Inhibitors
Elizabeth J. Davis et al.
ONCOLOGIST (2019)
Assessing the viability of transplanted gut microbiota by sequential tagging with D-amino acid-based metabolic probes
Wei Wang et al.
NATURE COMMUNICATIONS (2019)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Michael R. Cook et al.
JAMA ONCOLOGY (2019)
Side effects of immunotherapy: a constant challenge for oncologists
Florian Scotte et al.
CURRENT OPINION IN ONCOLOGY (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Blake M. Warner et al.
ONCOLOGIST (2019)
Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
Anne Rogiers et al.
JOURNAL OF ONCOLOGY (2019)
Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease
Joshua Korzenik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
Yara van Holstein et al.
DRUGS & AGING (2019)
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events
Jarushka Naidoo et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis
Joe-Elie Salem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adverse Events Following Cancer Immunotheraoy: Obstacles and Opportunities
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2019)
The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors
Julia Lai-Kwon et al.
JOURNAL OF CANCER SURVIVORSHIP (2019)
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
Michael S. Hughes et al.
CANCER MEDICINE (2019)
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
Audrey Simonaggio et al.
JAMA ONCOLOGY (2019)
Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy
Ahmed Mekki et al.
EUROPEAN JOURNAL OF CANCER (2019)
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Divyanshu Dubey et al.
NEUROLOGY (2019)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
Christian D. Sadik et al.
FRONTIERS IN IMMUNOLOGY (2019)
Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database
Kenichiro Sato et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors A single-center experience
Aneet Kaur et al.
MEDICINE (2019)
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
Salahaldin A. Tahir et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Yeonghee Eun et al.
SCIENTIFIC REPORTS (2019)
Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
Marie Kostine et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis
Jingli Lu et al.
CANCER MEDICINE (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases
Michael Schwarz et al.
CLINICAL LUNG CANCER (2019)
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
Alvaro Moreira et al.
EUROPEAN JOURNAL OF CANCER (2019)
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Y. Kanjanapan et al.
EUROPEAN JOURNAL OF CANCER (2019)
Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs
Arianna Draghi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Delivery technologies for cancer immunotherapy
Rachel S. Riley et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients
Michael D. Richter et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
Emma C. de Moel et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Pictorial Essay of Immunotherapy: Complications that Internists Will See, Whether They Like it or Not
Ashley Evens et al.
AMERICAN JOURNAL OF MEDICINE (2019)
Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy
Karen Bitton et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
David Hsiehchen et al.
JAMA NETWORK OPEN (2019)
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells
Nathan Simon et al.
JCI INSIGHT (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
Merav Lidar et al.
AUTOIMMUNITY REVIEWS (2018)
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Katharina C. Kaehler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Hannah M. Knochelmann et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment
H. Picchi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)
J. W. Baddley et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)
G. Redelman-Sidi et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Vasculitis associated with immune checkpoint inhibitors-a systematic review
Anisha Daxini et al.
CLINICAL RHEUMATOLOGY (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C. Leonardi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective
Dipti M. Karamchandani et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies
Teerin Liewluck et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Syed S. Mahmood et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors
Ioannis Gkiozos et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Cardiorenal complications of immune checkpoint inhibitors
Krishna Sury et al.
NATURE REVIEWS NEPHROLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy
Sagun Parakh et al.
ONCOLOGIST (2018)
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
Laura C. Cappelli et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Aaron Lisberg et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C. Santini et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution
Celine Anquetil et al.
CIRCULATION (2018)
Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?
Spyros I. Siakavellas et al.
CURRENT OPINION IN GASTROENTEROLOGY (2018)
Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors
Yasuo Hamamoto et al.
FUTURE ONCOLOGY (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Reporting of immune checkpoint inhibitor-associated myocarditis
Sadeer G. Al-Kindi et al.
LANCET (2018)
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Mehdi Touat et al.
NEUROLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study
Georg Richtig et al.
PLOS ONE (2018)
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
Sabina Sandigursky et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship
Lina Petersone et al.
FRONTIERS IN IMMUNOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Predictors of immunotherapy-induced immune-related adverse events
A. Kartolo et al.
CURRENT ONCOLOGY (2018)
Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events
Dirk H. Wijn et al.
EUROPEAN JOURNAL OF CANCER (2018)
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio et al.
EUROPEAN JOURNAL OF CANCER (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
Arabella Young et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
Elena Gianchecchi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
Nicolas Delanoy et al.
Lancet Haematology (2018)
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Monica Girotra et al.
JNCI CANCER SPECTRUM (2018)
Clinical assessment of immune-related adverse events
Aaron Sosa et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H. Geukes Foppen et al.
ESMO OPEN (2018)
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study
Marie Kostine et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies
Kristina Buder-Bakhaya et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M. H. Pollack et al.
ANNALS OF ONCOLOGY (2018)
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Tomoko Kobayashi et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
Vincent Sibaud
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Laura C. Cappelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in PatientsWith Metastatic Solid Tumors
Shruti Agrawal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Ralf Gutzmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
D. Makarious et al.
EUROPEAN JOURNAL OF CANCER (2017)
Health-related quality of life results from the phase III CheckMate 067 study
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2017)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
S. Cuzzubbo et al.
EUROPEAN JOURNAL OF CANCER (2017)
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis
Sebastien Le Burel et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
Cindy Franklin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Immune checkpoint inhibitors and elderly people: A review
Amaury Daste et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
David J. Byun et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan
Shigeaki Suzuki et al.
NEUROLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Autoimmune Cardiotoxicity of Cancer Immunotherapy
Feixiong Cheng et al.
TRENDS IN IMMUNOLOGY (2017)
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature
Laura C. Cappelli et al.
ARTHRITIS CARE & RESEARCH (2017)
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid
Laura Sowerby et al.
JAMA DERMATOLOGY (2017)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo De Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Immunotherapy-associated autoimmune hemolytic anemia
Uqba Khan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Sang Taek Kim et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Neurological toxicities associated with immune-checkpoint inhibitors
Mehdi Touat et al.
CURRENT OPINION IN NEUROLOGY (2017)
HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma
A. S. Koksal et al.
ANNALS OF ONCOLOGY (2017)
The Importance of Immunization in Cancer Prevention, Treatment, and Survivorship
Elizabeth M. Ward et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
L. Khoja et al.
ANNALS OF ONCOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol et al.
CANCER TREATMENT REVIEWS (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
Elizabeth H. Byrne et al.
CANCER (2017)
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
Jessica C. Hassel et al.
CANCER TREATMENT REVIEWS (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Rimda Wanchoo et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
S. Kanameishi et al.
ANNALS OF ONCOLOGY (2016)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Effect of nivolumab on health-related quality of life in patients with treatment-na⟨ve advanced melanoma: results from the phase III CheckMate 066 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2016)
CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
Bernice Lo et al.
BLOOD (2016)
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Jonathan M. Pitt et al.
CANCER RESEARCH (2016)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Simone M. Goldinger et al.
CLINICAL CANCER RESEARCH (2016)
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Eduard Cornelis Verschuren et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma
Maria Del Castillo et al.
CLINICAL INFECTIOUS DISEASES (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Endocrinological side-effects of immune checkpoint inhibitors
Francesco Torino et al.
CURRENT OPINION IN ONCOLOGY (2016)
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
V. R. Belum et al.
EUROPEAN JOURNAL OF CANCER (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar et al.
KIDNEY INTERNATIONAL (2016)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Katrin Klocke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study
Mitsuhiro Akiyama et al.
RHEUMATOLOGY INTERNATIONAL (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer
Tanya J. Williams et al.
JAMA NEUROLOGY (2016)
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer A Systematic Review and Meta-analysis
Mizuki Nishino et al.
JAMA ONCOLOGY (2016)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson et al.
JAMA ONCOLOGY (2016)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
Naoka Murakami et al.
CLINICAL KIDNEY JOURNAL (2016)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab
Ugur Uslu et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Measurement of anti-drug antibodies to biologic drugs. A sexy trend-or is it clinically meaningful?
Anna Felis-Giemza et al.
RHEUMATOLOGY (2015)
Artificial Intelligence, Big Data, and Cancer
Hagop Kantarjian et al.
JAMA ONCOLOGY (2015)
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Ahmad A. Tarhini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
Melissa Noack et al.
AUTOIMMUNITY REVIEWS (2014)
PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile
Carolina Pizarro et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Vanna Chiarion Sileni et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Opportunistic autoimmune disorcers potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
Yi-chi M. Kong et al.
FRONTIERS IN IMMUNOLOGY (2014)
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Salvatore Maria Corsello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
Kira Minkis et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
Stefania Laurent et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Caroline J. Voskens et al.
PLOS ONE (2013)
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
Yago Pico de Coana et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Inessa Schwab et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
Stephanie Andrews et al.
Cancer Management and Research (2012)
The role of the PD-1 pathway in autoimmunity and peripheral tolerance
Brian T. Fife et al.
YEAR IN IMMUNOLOGY (2011)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Hemophilia A Induced by Ipilimumab
Julie Delyon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
Erika von Euw et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Anti-CTLA4 Antibody-Induced Lupus Nephritis.
Fouad Fadel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell-mediated injury in the heart
Nir Grabie et al.
CIRCULATION (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice
T Okazaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
YE Latchman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Development of autoantibodies before the clinical onset of systemic lupus erythematosus
MR Arbuckle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice
T Okazaki et al.
NATURE MEDICINE (2003)
An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies
B Vaidya et al.
RHEUMATOLOGY (2002)
分享论文
